A Phase 3 interventional study of Lidocaine and Placebo in Anesthesia, sponsored by Hopital Foch. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-03.
Sponsored by Hopital Foch · Phase 3, Interventional, and Treatment
The objective is to evaluate the sparing effect of Lidocaine on doses of propofol and remifentanil.
Hopital Foch is the lead sponsor of 208 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Lidocaine
Drug: Lidocaine
patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
Drug: Placebo
bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia. start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine
NaCl 9/00 (same volume as in the lidocaine group) start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00
administered dose of propofol during maintenance of anesthesia
Time frame: day 1
administered dose of propofol during induction of anesthesia
Time frame: day 1
administered doses of remifentanil during induction and maintenance of anesthesia
Time frame: day 1
delay (measured as minutes) between the end of propofol and remifentanil administration and the recovery from anesthesia
Time frame: day 1
hemodynamic abnormalities requiring treatment
Time frame: day 1
% of time with a BIS index between 40 and 60
Time frame: day 1
postoperative morphine requirement
Time frame: day 1
incidence of postoperative nausea and vomiting
Time frame: day 1
% of patients with an explicit memorisation of the intraoperative period
Time frame: second postoperative day
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hopital Foch